Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

31 October 2014

Swedish drugmaker Medivir (OMX: MVIR) says it has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with Olysio (simeprevir).

Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), and Medivir and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Medivir has rights to the drug in the Nordic region. Olysio generated global sales for J&J of $796 million for the third quarter of 2014.

Sweden’s Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment with Olysio is beneficial from a health economics viewpoint in the treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of previous treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK